Consolidated Portfolio Review Corp Eli Lilly & CO Transaction History
Consolidated Portfolio Review Corp
- $448 Billion
- Q3 2024
A detailed history of Consolidated Portfolio Review Corp transactions in Eli Lilly & CO stock. As of the latest transaction made, Consolidated Portfolio Review Corp holds 1,071 shares of LLY stock, worth $852,162. This represents 0.21% of its overall portfolio holdings.
Number of Shares
1,071
Previous 5,601
80.88%
Holding current value
$852,162
Previous $5.07 Billion
81.28%
% of portfolio
0.21%
Previous 1.18%
Shares
7 transactions
Others Institutions Holding LLY
# of Institutions
4,011Shares Held
751MCall Options Held
8.27MPut Options Held
10.5M-
Lilly Endowment Inc Indianapolis, IN96.9MShares$77.1 Billion0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA73.8MShares$58.7 Billion1.2% of portfolio
-
Black Rock Inc. New York, NY65.9MShares$52.4 Billion1.37% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA51.4MShares$40.9 Billion29.2% of portfolio
-
State Street Corp Boston, MA33.9MShares$26.9 Billion1.24% of portfolio
About ELI LILLY & Co
- Ticker LLY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 950,174,976
- Market Cap $756B
- Description
- Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...